DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Thursday, December 31, 2009

GlaxoSmithKline receives positive EU opinion for Eltrombopag

GlaxoSmithKline has revealed that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Revolade (eltrombopag) ? a drug intended to treat reduced platelet count, or thrombocytopenia, in adults with the blood disorder chronic immune thrombocytopenic purpura (ITP).

Marketing authorisation has been granted by the CHMP for eltrombopag in the EU for the treatment of ITP in adults who have had their spleen removed and later fail to respond to corticosteroids and immunoglobulins therapies.

The oral compound may also be considered as a second-line therapy for adult patients where surgery to remove their spleen is contraindicated, the firm added.

Paolo Paoletti, senior vice-president and global head of oncology research and development at GlaxoSmithKline, commented: "Eltrombopag is an innovative treatment for thrombocytopenia in patients with chronic ITP. This once-a-day tablet is able to stimulate platelet production and reduce the risk of bleeding in a difficult-to-treat disease."

Earlier this week, GlaxoSmithKline announced that it will work alongside NanoBio to develop the latter firm's over-the-counter cold sore treatment NB-001.

Claim Your Free Book "Make Real Money On the Internet"

No comments: